Trial Profile
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2022
Price :
$35
*
At a glance
- Drugs Ladarixin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Sponsors Dompe Farmaceutici
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 16 Jun 2020 Primary endpoint (Efficacy endpoint) has not been met, as per Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association